Health Care and Life Sciences

Pharmaceutical Industry

Pharmaceutical Industry

NERA has provided economic analysis in testimony and written reports to many of the leading international research-based and generic pharmaceutical companies. We have performed competitive analyses of proposed acquisitions involving pharmaceutical companies as well as estimated damages or costs in contract, antitrust, patent, and regulatory matters. We also have expertise in providing companies with economically sound transfer pricing methodologies and strategic planning advice. Our work has encompassed both chemical based and biotechnology products. In our pharmaceutical work, we have:

  • Analyzed market definition and entry conditions in horizontal mergers involving pharmaceutical manufacturers as well as pharmaceutical wholesalers;
  • Analyzed the competitive impact of pharmaceutical companies acquiring pharmaceutical benefit managers;
  • Calculated damages in a wide variety of antitrust, contract dispute, and patent infringement matters in the pharmaceutical industry;
  • Assessed market definition, market share, and entry conditions in antitrust counter-claims, which often evolve in patent infringement cases;
  • Made presentations to the federal antitrust agencies on the competitive effects of brand elimination and innovation markets;
  • Advised pharmaceutical companies on the business implications of competitive trends, regulatory changes, and health care reform;
  • Conducted transfer pricing studies for pharmaceutical firms under US, OECD, and foreign tax guidelines; and
  • Conducted public policy studies on intellectual property protection, parallel trade, health care reform, Medicare prescription drug proposals, and pricing investigations as they affect the pharmaceutical industry.

NERA also participates in policy discussions concerning the risks and returns of pharmaceutical research and development, and advises pharmaceutical companies on the business implications of competition, regulation, and health care reform. Our economists analyze emerging public policy issues such as the effects of regulatory delays in approving pharmaceutical products on public health and consequences of developing countries ignoring TRIPS standards on local pharmaceutical industry growth. Our economists also provide analysis of the strength of intellectual property protection and its implications for drug prices and the pace of pharmaceutical research around the world, valuation of research and development pipelines, and pricing of tangible and intangible assets in intracompany and intercompany transactions.
 
Our experts also are experienced in the assessment of economic costs and benefits of therapeutic studies, the comparative evaluation of alternative means for controlling pharmaceutical costs by competitive and regulatory means, and assistance in evaluating reimbursement methodologies. Our experts advise on transfer pricing, valuation of patents, questions related to efficiency, cost containment, intellectual property rights, and industrial policies that support a strong research-based pharmaceutical industry by providing commentary and analysis of the requirements of an equitable and efficient health care system and how reform efforts impact the pharmaceutical industry.

Name Title Location Phone Email
Dr. Sumanth Addanki Managing Director White Plains, NY +1 914 448 4060 sumanth.addanki@nera.com
Dr. Graeme Hunter Managing Director New York City +1 212 345 7724 graeme.hunter@nera.com
Dr. Thomas McCarthy Managing Director
Health Care Practice Chair
Los Angeles +1 213 346 3005 thomas.mccarthy@nera.com
Dr. Christine Siegwarth Meyer Managing Director White Plains, NY +1 914 448 4119 christine.meyer@nera.com
Dr. Ramsey Shehadeh Managing Director New York City +1 212 345 6089 ramsey.shehadeh@nera.com
Title Type Author
Paper Trail: Review of a Recent Working Paper on the Effect of Copay Coupons on Drug ... Published Article The Antitrust Source
High Court Brings Economics Back To Pay-For-Delay Analysis Published Article By Dr. Sumanth Addanki, Dr. Alan Daskin, and Dr. Christine Siegwarth Meyer
How Much Does that Medication Cost? A Study of Medicare Beneficiaries' Knowledge of O... Study By Dr. Eugene Ericksen and Melissa Pittaoulis
An Analysis of Price Effects from Drug Shortages for Independent Pharmacies and the P... Working Paper By Dr. Graeme Hunter
Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development E... Working Paper By Dr. Graeme Hunter with Dr. John Vernon and Dr. Joseph Cook
The Future Costs, Risks, and Rewards of Drug Development: The Economics of Pharmacoge... Published Article By Dr. Graeme Hunter with Dr. John Vernon and Dr. Joseph Cook
Reimbursing Generics in the UK: Is There a Better Way? Published Article By NERA Special Advisor Ian Senior
A Comparables Approach To Measuring Cash-Flow-At-Risk (c-far) For Non-Financial Firms Working Paper By Louis Guth and Dr. Michael Tennican, et al.
Modern Methods For the Valuation of Intellectual Property Report By Drs. Richard Rapp and Lauren Stiroh